Day One Biopharmaceuticals
NASDAQ · DAWN·Brisbane, CA·Small-cap·Approved
Commercial-stage oncology biopharma focused on pediatric and adult cancers. OJEMDA (tovorafenib) is FDA-approved for pediatric low-grade glioma. Pipeline includes pimasertib (MEK1/2) and DAY301 (PTK7-targeted ADC).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Day One Corporate Presentation | Corporate overview | April 15, 2026 | 43 |